Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2017 ASCO Annual Meeting /
Halving duration of ADT for high risk prostate cancer patients

2nd - 6th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.17
Views: 1508

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada

Prof Nabid speaks with ecancer at ASCO 2017 about the non-inferiority of 18 months of androgen deprivation therapy to 36 months for high-risk prostate cancer.

Across multiple scales and points, Prof Nabid highlights the equal clinical outcomes, better patient quality of life and significant reductions in cost and toxicity for patients receiving the shorter course of ADT with initial radiotherapy.

Considering the time and resource investment in reaching these results, he describes further investigation to find a minimum dosage duration for equivalent outcomes as unlikely, especially considering the recent successes with abiraterone for prostate cancer.

These findings were discussed further by Prof Charles Ryan and Dr Chris Parker here.

For more prostate cancer updates, tune in to the ecancer prostate symposium.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation